Coherent Raman Imaging
Label-free chemometric imaging for objective,
AI-assisted cell analysis and tissue diagnosis
CRI brings together ultra-fast fibre based lasers and Coherent Raman scattering microscopy to make high-speed truly label free imaging possible, scanning tumour tissue in seconds.
Investors
The company is
in partnership with
Is your company interested
in CRI technology?
The company has received grant funding from
The company is a spinout of
News
Latest on chemometric imaging
Cambridge Raman Imaging presents new technology at Frontier IP Showcase
Developing new medical technologies based on high-speed, low-cost Raman digital imaging and artificial intelligence has the potential to transform...
CRI is featured in the Market Map of the leading European healthcare companies
Glad to be featured in the Market Map of the leading European healthcare companies 2022 curated by AlbionVC - which aims to “Captures the...
CRI raises 1.1 million to accelerate scale up through an equity funding round
Cambridge Raman Imaging has raised £1.1 million through an equity funding round from existing and new investors, bringing CRI value at £6.1 million...
Cambridge Raman Imaging has been selected to coordinate a European Union grant to transform cancer diagnosis and treatment
Cambridge Raman Imaging (“CRI” or the “Company”) announces today it will coordinate a project selected to receive a €3.3 million grant in the...